Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Biotechnology ETF (NQ:IBB)

213.56 +2.73 (+1.29%)
Official Closing Price Updated: 4:15 PM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
News headline image
2 Biotech Stocks Shaping Up for Major Breakouts ↗
Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts. 
Via MarketBeat
Topics ETFs
News headline image
Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB? ↗
IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance? ↗
First Trust's 30-stock strategy delivered 53.2% returns over one year, but comes with higher concentration risk and a steeper 11-basis-point fee. 
Via The Motley Fool
Topics ETFs
PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business? ↗
Via Stocktwits
News headline image
IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy? ↗
Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years. 
Via The Motley Fool
Topics ETFs
News headline image
Vanguard Health Care vs. iShares Biotech: How Do These ETFs Stack Up? ↗
Broad healthcare diversification or concentrated biotech growth? Compare cost, risk, and portfolio composition to find your fit. 
Via The Motley Fool
Topics ETFs
News headline image
SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns ↗
Compare portfolio diversity, risk profiles, and income potential as you weigh these two leading healthcare ETFs. 
Via The Motley Fool
Topics ETFs
News headline image
5 Places Investors Can Hide If the AI Trade Keeps Cracking ↗
As AI stocks face volatility, capital is rotating into biotech, industrials, utilities, consumer staples, and dividend ETFs showing relative strength. 
Via MarketBeat
Topics Artificial Intelligence ETFs
News headline image
MarketBeat Week in Review – 06/22 - 06/26 ↗
SpaceX IPO buzz faded as AI volatility, hotter inflation, and a shortened trading week shifted investor focus toward earnings season 
Via MarketBeat
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗
The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout. 
Via MarketBeat
Topics ETFs
News headline image
2 Ways to Play the Big Pharma Patent Cliff ↗
With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize. 
Via MarketBeat
Topics ETFs Intellectual Property
News headline image
Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally
In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF... 
Via MarketMinute
Topics ETFs Intellectual Property Stocks
News headline image
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but... 
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance
News headline image
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure ↗
H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure. 
Via Stocktwits
Topics Initial Public Offering
News headline image
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗
Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month. 
Via Stocktwits
News headline image
Why Did CRMD Stock Tumble Over 11% Today? ↗
The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Why Did BTAI Stock Surge 20% In Pre-Market Today? ↗
BioXcel announced positive Phase 2 results for evaluating treatment for opioid withdrawal symptoms. 
Via Stocktwits
News headline image
Why Did CDXS Stock Jump 7% Today? ↗
The company tied up with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA using a proprietary ECO Synthesis platform. 
Via Stocktwits
News headline image
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial ↗
Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome. 
Via Stocktwits
News headline image
AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates ↗
Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data. 
Via Stocktwits
News headline image
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗
Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12. 
Via Stocktwits
News headline image
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market ↗
Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data 
Via Stocktwits
News headline image
Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗
Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal. 
Via Stocktwits
News headline image
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition ↗
The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio. 
Via Stocktwits
News headline image
CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗
COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
News headline image
CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗
The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
News headline image
HUMA Stock Just Shot Up 12% Today – Here’s Everything To Know About The DOD Funding Fueling The Surge ↗
The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration. 
Via Stocktwits
News headline image
Why Is ALVO Stock Rising Pre-Market Today? ↗
The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints. 
Via Stocktwits
News headline image
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative... 
Via MarketMinute
Topics ETFs Government Initial Public Offering
News headline image
Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗
Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.